Because ADAM17 is the subsequent step following FGFR2 activation in migration and proliferation of EM cells, targeting ADAM17 function in FGFR2‐mutant EC cells may have a beneficial effect in tumour suppression. Here, FGFR2 is linked to neoplasm.